Ignite Creation Date:
2025-12-24 @ 4:01 PM
Ignite Modification Date:
2026-02-02 @ 1:22 PM
Study NCT ID:
NCT02235766
Status:
UNKNOWN
Last Update Posted:
2016-03-04
First Post:
2014-09-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Corelab Remotely Echocardiographic Imaging Acquisition in Cardiac Resynchronization Therapy Candidates
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006333', 'term': 'Heart Failure'}], 'ancestors': [{'id': 'D006331', 'term': 'Heart Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'CASE_ONLY'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 50}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2015-03'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2016-03', 'completionDateStruct': {'date': '2017-06', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2016-03-03', 'studyFirstSubmitDate': '2014-09-03', 'studyFirstSubmitQcDate': '2014-09-05', 'lastUpdatePostDateStruct': {'date': '2016-03-04', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2014-09-10', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2017-06', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'ECM assessment', 'timeFrame': '6 months', 'description': 'Agreement in the echocardiographic measurement capability (EMC) between transmitted and echocardiographic device image on the set of high quality images transmitted by STE. Each echo image will be classified as high quality image if the Mean Opinion Score (MOS) will be greater than 3 points. For each high quality echo image (MOS greater or equal 3) the EMC will be assessed to both transmitted and device echocardiographic image.'}], 'secondaryOutcomes': [{'measure': 'Prognostic efficacy of specific echo parameters', 'timeFrame': '6 months', 'description': 'Echocardiographic response defined as LVESV reduction ≥10% at 6 months after CRT-D implantation.'}, {'measure': 'Clinical composite score CCS', 'timeFrame': '6 months', 'description': 'CCS describing patients regardless of vital status at 6 months and includes both objective and subjective measures of clinical status.'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Cardiac Resynchronization Therapy', 'Satellite Tele-Echocardiography'], 'conditions': ['Heart Failure']}, 'descriptionModule': {'briefSummary': 'Purpose of the observational study is to assess the capability of a satellite tele-echocardiography (STE) system to acquire and transmit echocardiographic images and clips to an echocardiographic core laboratory (ECL) in a real time mode without loss of quality. Additionally the prognostic efficacy of specific echo parameters in the cardiac resynchronization therapy response will be evaluated.', 'detailedDescription': 'CORELAB-CRT is a prospective multi center Italian observational study. All echo images and clips will be transmitted by using an integrated satellite transmission system. All echo assessments performed in accordance to the centers clinical practice will be also used to investigate the prognostic efficacy of echo parameters in term of response to the cardiac resynchronization therapy (CRT). All commercially available multi-chamber CRT-D devices from any manufacturers are allowed in this observational study.\n\nAny compatible market released right atrial, right ventricular and left ventricular lead from any manufacturer is allowed.\n\nThe echocardiography device models used to perform echo imaging for all patients participating in this analysis are GE Vivid 7, GE Vivid 9 and GE Vivid I, according to the model used in the clinical practice of the hospital.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'In accordance with the current ESC/ACCF/AHA indications for CRT in sinus rhythm, all patients in NYHA class II, III and IV with QRS complex greater than 120 msec and ejection fraction equal or less than 35% will be considered eligible to participate in this observational study.', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. NYHA class II, III and ambulatory IV with:\n\n * QRS complex duration ≥120msec;\n * Ejection fraction ≤35%.\n2. Optimized medical treatment;\n3. Patient in sinus rhythm;\n4. Patient is willing and able to sign an informed consent form.\n\nExclusion Criteria:\n\n1. Unstable angina, or acute myocardial infarction, coronary-aortic bypass graft or percutaneous transluminal coronary angioplasty within the past 3 months;\n2. Cerebral vascular attacks or transient ischemic attack within the last month;\n3. Chronic atrial arrhythmias, paroxysmal atrial fibrillation events;\n4. Patients already implanted with an ICD or a CRT device;\n5. Pacemaker dependency or ventricular pacing percentage ≥10%;\n6. Valvular disease with an indication for surgical correction ≤12 months survival expectancy;\n7. Mechanical right ventricular valve;\n8. Patient is enrolled in or intends to participate in another clinical trial that may have an impact on the study endpoints;\n9. Pregnancy or breastfeeding;\n10. Previous heart transplant;\n11. Refusal of study informed consent;\n12. Expected lack of compliance during follow-up;\n13. Patient is less than 18 years of age;\n14. Patient's life expectancy is less than 6 months in the opinion of physician."}, 'identificationModule': {'nctId': 'NCT02235766', 'acronym': 'CORELAB-CRT', 'briefTitle': 'Corelab Remotely Echocardiographic Imaging Acquisition in Cardiac Resynchronization Therapy Candidates', 'organization': {'class': 'OTHER', 'fullName': 'Kell s.r.l.'}, 'officialTitle': 'Corelab Remotely Echocardiographic Imaging Acquisition in Cardiac Resynchronization Therapy Candidates', 'orgStudyIdInfo': {'id': 'Kell-1'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'CRT candidates patients', 'description': 'In accordance with the current ESC/ACCF/AHA indications for CRT in sinus rhythm, all patients in NYHA class II, III and IV with QRS complex greater than 120 msec and ejection fraction equal or less than 35% will be considered eligible to participate in this observational study.', 'interventionNames': ['Other: Echocardiographic assessment']}], 'interventions': [{'name': 'Echocardiographic assessment', 'type': 'OTHER', 'armGroupLabels': ['CRT candidates patients']}]}, 'contactsLocationsModule': {'locations': [{'zip': '02100', 'city': 'Rieti', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Serafino Orazi, MD', 'role': 'CONTACT'}, {'name': 'Serafino Orazi, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Giuseppe Stifano, MD', 'role': 'SUB_INVESTIGATOR'}], 'facility': 'S.Camillo de Lellis Hospital', 'geoPoint': {'lat': 42.40476, 'lon': 12.85735}}, {'zip': '00144', 'city': 'Rome', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Filippo Lamberti, MD', 'role': 'CONTACT'}, {'name': 'Filippo Lamberti, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Francesca Di Clemente, MD', 'role': 'SUB_INVESTIGATOR'}], 'facility': 'S.Eugenio Hospital', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'zip': '00144', 'city': 'Rome', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Simona Mega, MD', 'role': 'CONTACT'}, {'name': 'Simona Mega, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Danilo Ricciardi, MD', 'role': 'SUB_INVESTIGATOR'}], 'facility': 'University Hospital Campus Bio-Medico', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'zip': '00186', 'city': 'Rome', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Gaetano Luca Panetta, MD', 'role': 'CONTACT'}, {'name': 'Gaetano Luca Panetta, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Francesca Toscano, MD', 'role': 'SUB_INVESTIGATOR'}], 'facility': 'Fatebenefratelli Hospital', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}], 'centralContacts': [{'name': 'Cesare Aragno', 'role': 'CONTACT', 'email': 'caragno@kell.it', 'phone': '+39 06 36004916'}], 'overallOfficials': [{'name': 'Carlo Peraldo Neja', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'CORELAB Responsible'}, {'name': 'Cesare Aragno', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Kell s.r.l.'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Kell s.r.l.', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}